Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eli Lilly, Shionogi to Codevelop, Comarket Duloxetine in Japan
February 19, 2007
- Japan, EU Reach Agreement on Confidentiality of Drug Information
February 19, 2007
- Chugai: Sales, Profits Impacted by NHI Price Cuts
February 19, 2007
- REGULATORY NEWS IN BRIEF
February 19, 2007
- Companies Gearing Up for Pollinosis Season
February 19, 2007
- Sawai's New 3-Year Plan to Focus on New Formulations, Data Supply
February 19, 2007
- BUSINESS NEWS IN BRIEF
February 19, 2007
- Nihon Chouzai: Profits Hit By GE Drug Promotion Costs
February 19, 2007
- About 17% of Prescriptions Permit GE Substitution: Survey
February 19, 2007
- Sawai, Nichi-Iko Top GE Drug Suppliers to Hospitals: Survey
February 19, 2007
- MEDICAL DEVICE NEWS IN BRIEF
February 19, 2007
- Nippon Shinyaku to Commercialize RNA Drug Discovery Technology
February 19, 2007
- TS-1 Adjuvant Therapy Reduces Mortality in Gastric Cancer
February 19, 2007
- MCH Group's ZoeGene Corp. to Be Reorganized
February 19, 2007
- New GL for Stomach Cancer Screening Expected by March
February 19, 2007
- Tohoku Univ. Researchers Develop New Endoscopic Laser Treatment System
February 12, 2007
- Olympus Applies for Swallowable Imaging Capsule
February 12, 2007
- PREMINENT Opens Door to Combination Drugs
February 12, 2007
- Olympus Launches World's First AFT Videoscopes
February 12, 2007
- GENERIC NEWS IN BRIEF
February 12, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…